| GlaxoSmithKline: FDA panel backs Votrient for kidney cancer but hurdles remain - Trading Markets (press release) |
|
|
Trading Markets (press release)Following the panel voting 10-0 in favor of Votrient (pazopanib; GlaxoSmithKline) in the treatment of advanced renal cell carcinoma (RCC), the FDA has until ... read more |